MARKET

ERAS

ERAS

Erasca, Inc.
NASDAQ
15.48
-0.13
-0.83%
Pre Market: 15.70 +0.22 +1.42% 09:13 11/11 EST
OPEN
15.43
PREV CLOSE
15.61
HIGH
15.67
LOW
15.00
VOLUME
104
TURNOVER
0
52 WEEK HIGH
24.28
52 WEEK LOW
2.210
MARKET CAP
5.41B
P/E (TTM)
-16.2128
1D
5D
1M
3M
1Y
5Y
1D
Erasca's Cash Runway Could End Before Its Pan-RAS Bet Pays Off
Barchart · 22h ago
Weekly Report: what happened at ERAS last week (1102-1106)?
Weekly Report · 2d ago
Erasca (ERAS) Could Be 45% Undervalued On New Cancer Trial Progress
Simply Wall St · 5d ago
What Erasca (ERAS)'s Cancer Drug Trial Start Means For Shareholders
Simply Wall St · 6d ago
Tango, Erasca Open Phase 1/2 Combination Trial Enrollment In Pancreatic And Lung Cancers
NASDAQ · 6d ago
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 6d ago
Tango Therapeutics, Erasca initiate vopimetostat with ERAS-0015 study
TipRanks · 6d ago
Weekly Report: what happened at ERAS last week (1026-1030)?
Weekly Report · 11/02 10:10
More
About ERAS
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.

Webull offers Erasca Inc stock information, including NASDAQ: ERAS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ERAS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ERAS stock methods without spending real money on the virtual paper trading platform.